Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWSC5L)

Drug Name
L-778123 Drug Info
Synonyms
183499-57-2; L-778123; UNII-31ZXM8ZKQ3; 4-[(5-{[4-(3-CHLOROPHENYL)-3-OXOPIPERAZIN-1-YL]METHYL}-1H-IMIDAZOL-1-YL)METHYL]BENZONITRILE; 31ZXM8ZKQ3; CHEMBL279433; 4-((5-((4-(3-chlorophenyl)-3-oxopiperazin-1-yl)methyl)-1H-imidazol-1-yl)methyl)benzonitrile; L-778123 free base; 4-[[5-[[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl]imidazol-1-yl]methyl]benzonitrile; 4-[(5-{[4-(3-chlorophenyl)-3-oxopiperazin-1-yl]methyl}imidazol-1-yl)methyl]benzonitrile; SCHEMBL1683541; AC1L50Q0; CTK7C7787; 1s63; 1s64; BDBM50097071; ZINC53070632
Indication
Disease Entry ICD 11 Status REF
Lymphoma 2A80-2A86 Phase 1 [1]
Cross-matching ID
PubChem CID
216454
CAS Number
CAS 183499-57-2
TTD Drug ID
DMWSC5L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Farnesyl protein transferase (Ftase)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lonafarnib DMGM2Z6 Hutchinson-Gilford progeria syndrome LD2B Approved [3]
Zarnestra DMF30HL Acute myeloid leukaemia 2A60 Phase 3 [4]
GGTI-2418 DM8U23L Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
BMS214662 DM5M48F Non-small-cell lung cancer 2C25.Y Phase 1 [6]
L-745631 DM4UP7R Solid tumour/cancer 2A00-2F9Z Terminated [7]
ABT-839 DM4UN9A Non-small-cell lung cancer 2C25.Y Terminated [8]
MANUMYCIN A DM1SWOY N. A. N. A. Terminated [9]
SCH-44342 DMUL4VX N. A. N. A. Terminated [10]
RPR-113829 DMJ63GW N. A. N. A. Terminated [11]
RPR-114334 DMAIJT6 N. A. N. A. Terminated [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Geranylgeranyl transferase I (GGTase-I)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-745631 DM4UP7R Solid tumour/cancer 2A00-2F9Z Terminated [7]
GGTI-298 DM1CG0J N. A. N. A. Terminated [12]
PD-83176 DMSIMKZ Discovery agent N.A. Investigative [13]
A-313326 DML4P6O Discovery agent N.A. Investigative [14]
J-109,390 DM9SFGB Discovery agent N.A. Investigative [15]
L-269,289 DMV6018 Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Farnesyl protein transferase (Ftase) TTXQKM3 FNTA_HUMAN; FNTB_HUMAN Modulator [2]
Geranylgeranyl transferase I (GGTase-I) TTX20QP PGTB1_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00003430) L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors. U.S. National Institutes of Health.
2 Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
4 Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep;2(3):491-500.
5 Company report (Prescient)
6 Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004 Oct;18(10):1599-604.
7 Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90.
8 Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1359-62.
9 A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg Med Chem Lett. 2003 May 5;13(9):1523-6.
10 Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J Med Chem. 1999 Jun 17;42(12):2125-35.
11 Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7.
12 The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem. 1997 Oct 24;272(43):27224-9.
13 Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem. 1997 Jan 17;40(2):192-200.
14 Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorg Med Chem Lett. 2005 Jan 3;15(1):153-8.
15 Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes. J Bacteriol. 2000 Feb;182(3):704-13.